About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 

Company Statement

U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged

Bengaluru, Karnataka, India, Aug 31, 2019

"The U.S. FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for Insulin Glargine filed by our partner Mylan. The CRL has been issued pending completion of the Corrective And Preventive Actions (CAPAs) submitted to the U.S. FDA in response to the observations made at the conclusion of the pre-approval inspection of our insulin manufacturing facility in Malaysia in June 2019.

The CRL did not identify any outstanding scientific issues with the application. We remain confident of the quality of our application and do not anticipate any impact of this CRL on the commercial launch timing of our Insulin Glargine in the U.S.

We remain committed to global standards of Quality & Compliance and are working closely with our Partner and the regulator to complete these CAPAs to the satisfaction of the U.S. FDA."

- Company Spokesperson

<< Back

 

Download the notification
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved